Home > Boards > US Listed > Biotechs >

Qualigen Therapeutics Inc (QLGN)

Add QLGN Price Alert      Hide Sticky   Hide Intro
Moderator: Notabadguy
Search This Board: 
Last Post: 3/1/2021 9:41:54 AM - Followers: 7 - Board type: Free - Posts Today: 0

Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform.  The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002.  Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device.  By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville,  we are committed to providing exciting new therapeutic technologies to physicians and patients.

Click the Links Below for the Latest Presentations

As of February 1, 2021

Corporate Presentation

View H.C. Wainwright Bioconnect 2021 Conference Presentation

Therapeutics Pipeline
Qualigen has a diverse portfolio of proprietary drug candidates
FastPack® IP
The FastPack System is a proprietary diagnostics platform launched by Qualigen in 2001. This novel, rapid and highly accurate immunoassay testing system consists of the FastPack Analyzer and the FastPack test pouch; a single-use, disposable, foil packet which includes the FastPack reagent chemistry. Since the initial conception of the system, the Company has developed two versions of its analyzer and test pouch (1.0 and IP) and has expanded its assay menu to 10, including tests for prostate cancer, thyroid function, metabolic disorders and research applications. 

Clinical Trials
Qualigen and its strategic partners will be conducting clinical studies that explore the use of therapeutic product candidates developed by Qualigen in different cancer settings.  Approval by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is required to make our medicines available to patients. Therefore, our priority is to enroll patients in clinical trials in order to obtain the data required for review and approval by regulatory authorities.

Cancer Resources
To learn about cancer and available treatments, please visit the following:
• American Cancer Society – www.cancer.org
• National Institutes of Health – National Cancer Institute – www.cancer.gov




Michael S. Poirier
President, CEO and ChairmanMichael S. Poirier founded Qualigen in 1996 and is its Chairman, President and Chief Executive Officer.  Prior to founding Qualigen, Mr. Poirier was Vice President of Marketing for Ashirus Technologies, Inc., a Minneapolis-based manufacturer of innovative high-precision dispensing pumps and related equipment for the medical industry.  From 1993 to 1995, Mr. Poirier was Director of US Area Operations for EnSys, Inc., located in Research Triangle, North Carolina.  EnSys developed and manufactured field-portable immunoassay test kits for the environmental remediation industry.  From 1991 to 1993, Mr. Poirier was employed by Sanofi Pasteur in Chaska, Minnesota, as a Marketing Manager responsible for launching the ACCESS® Immunoassay System.  This novel diagnostic system was later acquired by Beckman-Coulter and is now one of the leading immunoassay test systems worldwide.  From 1985 to 1991, Mr. Poirier was employed by Abbott Diagnostics, a division of Abbott Laboratories, Inc. in various marketing and sales positions, including Worldwide Immunoassay Product Manager for the IMx® and AxSym® immunoassay diagnostic systems.  Both IMx and later, AxSym, became the leaders in their respective markets.  Prior to working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet.  Mr. Poirier holds a B.A. from Providence College and attended the University of Zürich, Switzerland, School of Law.

Wajdi Abdul-Ahad, PhD
Vice President, R&D, Chief Scientific Officer
Dr. Abdul-Ahad is Qualigen’s Vice President of Research and Development and Chief Scientific Officer. Since joining the Company in 2006, he has successfully developed and commercialized numerous complex immunoassays on both the FastPack and FastPack IP Systems.  In addition, Dr. Abdul-Ahad is responsible for all surface coating, nanotechnology and reagent manufacturing, as well as integration of new drug manufacturing systems and processes.  Prior to joining Qualigen, Dr. Abdul-Ahad led multifunctional design teams at Beckman Coulter that developed and commercialized over 15 assays on their industry leading Access and Synchron automated systems.  From 1988 to 1990, Dr. Abdul-Ahad held various management positions with the National Diagnostics Center and Noctech, Inc., both located in Galway, Ireland.  Dr. Abdul-Ahad holds a PhD in Biochemistry from National University of Ireland, Galway; an MS in Clinical Chemistry from the University of Surrey, England; an MBA from the University of La Verne, California and a BS in Pharmacy from the University of Baghdad, Iraq.  He also holds certifications and licenses from the American Board of Clinical Chemistry, State of California (Registered Pharmacist), National Registry of Clinical Chemistry and the National Academy for Clinical Biochemistry.  Dr. Abdul-Ahad’s professional affiliations include the Association of Clinical Biochemistry (ACB-UK), the American Association for Clinical Chemistry and the American Pharmaceutical Association.  Dr. Abdul-Ahad is also the author or co-author of numerous scientific publications.  
Amy S. Broidrick
Executive Vice President, Chief Strategy Officer
Ms. Broidrick held key roles in the successful worldwide launches and life cycle marketing of blockbuster drugs including Zetia™, VYTORIN™, and Celebrex™, and specialty brands. Since 2016, she served as Senior Vice President, Head of Corporate Development at Viking Therapeutics, responsible for building and implementing the US and global corporate and business development functions. Before that, she was Vice President, Head of Global Marketing Excellence and Business Innovation with EMD Serono, Inc, part of Merck KGaA (Germany), where she led global and country brand and launch planning, and strategic transformation initiatives. Ms. Broidrick was Vice President, Head of Marketing and Commercialization at Arena Pharmaceuticals, where she oversaw commercialization planning for a first-in-class obesity drug, and also led Portfolio Planning. Before Arena, she held roles of increasing responsibility at Merck & Co., and Pfizer (formerly GD Searle) including Global Brand Leader with P&L accountability. She led Merck & Co.’s new products marketing planning across brands and pipeline for the Asia Pacific region. Ms. Broidrick holds a BA from Fairleigh Dickinson University, completed further undergraduate studies at Wroxton College in England, and performed post-graduate work at Fairleigh Dickinson.
Christopher L. Lotz
Chief Financial Officer
Christopher L. Lotz joined Qualigen as Director of Finance in 2002 and was appointed Vice President and Chief Financial Officer in 2003.  Prior to joining Qualigen,  Mr. Lotz was Director of Finance for the United States subsidiaries of Bexcom, a procurement management software company based in Singapore from 1999 to 2001.  From 1998 to 1999 Mr. Lotz served as Controller of California Furniture Collections, Inc. a custom furniture manufacturer, and from 1987 to 1998 Mr. Lotz was Controller and then Vice President and Chief Financial Officer of Group Publishing, Inc. a book and magazine publisher.  Mr. Lotz holds a B.S. in Business Administration from Colorado State University.
Shishir K. Sinha
Vice President, Operations, Corporate Secretary
Shishir K. Sinha joined Qualigen as Vice President, Operations & QA/QC in 2006 and was appointed Corporate Secretary in 2017.  Prior to joining Qualigen, Mr. Sinha held leadership roles in the molecular diagnostics industry including Director of Manufacturing for Nanogen, and Senior Manager of Oligonucleotide Manufacturing for Celera Diagnostics from 2004-2006. From 2001-2004, Mr. Sinha served as Director of Manufacturing for Sequenom, a developer of industry leading methods and equipment to analyze DNA.  Mr. Sinha was Packaging Manager for Sandoz Pharmaceutics (Novartis) from 2000-2001, and from 1989 to 2000 held various management positions in QC, manufacturing, planning and production control with Microgenics Corp, a manufacturer of immunoassay diagnostic kits.  Mr. Sinha holds an MBEE in Biotechnology Enterprise from John Hopkins University and B.A. in Genetics from the University of California, Berkeley.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
QLGN News: Current Report Filing (8-k) 03/05/2021 09:16:05 AM
QLGN News: Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL 03/01/2021 08:30:00 AM
QLGN News: Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diag... 01/26/2021 09:00:00 AM
QLGN News: Current Report Filing (8-k) 01/06/2021 04:19:14 PM
QLGN News: Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference 01/05/2021 09:00:00 AM
#47   Qualigen Therapeutics Secures Option to Negotiate License for Notabadguy 03/01/21 09:41:54 AM
#46   i really this that this can go somewhere wrenchit 02/23/21 09:03:51 AM
#45   Still on watch. No hurry to buy in, Klinsmann 02/23/21 01:53:10 AM
#44   no body here dead board or not a wrenchit 02/22/21 05:10:41 PM
#43   We could use some news! I'm still long QLGN. Notabadguy 02/19/21 03:24:26 PM
#42   Plus, QLGN has great management. Check out ichael Notabadguy 02/08/21 10:32:52 AM
#41   This stock is about to make a big chainweight 02/06/21 01:55:40 PM
#40   You’re not, I’m here with you! Lol! chainweight 02/05/21 09:34:42 AM
#39   Whoa! It looks like I was right! QLGN Notabadguy 02/04/21 10:37:49 PM
#38   It looks like QLGN is picking up momentum. Notabadguy 02/04/21 02:19:03 PM
#37   **UPDATE** New investor presentation Notabadguy 02/03/21 09:32:14 PM
#36   Buying here stock1ace1 01/25/21 10:27:21 AM
#35   QLGN at $3.27 is $0.25 lower than where Notabadguy 12/22/20 12:33:32 PM
#34   * * $QLGN Video Chart 12-15-2020 * * ClayTrader 12/15/20 05:44:12 PM
#33   Same date, time, scenario here. Avg'd in @ 0whammies 10/16/20 10:12:48 AM
#32   July 13 2020 - We have already submitted RNsidersbuying 09/28/20 08:37:41 AM
#31   QLGN new member on board from yahoo fiance https://finance.yahoo.com/ne abcxyz 08/28/20 12:12:37 PM
#29   PRPO has to buy the test and are peterus 07/31/20 08:27:26 AM
#28   Bought QLGN on their announced shipping of test ShowMeThe$$$$$ 07/31/20 06:33:02 AM
#27   thanks peterus 07/30/20 04:45:25 PM
#26   O/S 16.83m Float 4.46 abingo 07/30/20 04:38:54 PM
#25   whats the O/S here ? peterus 07/30/20 02:17:57 PM
#24   Been in this since 6am on July 1st Witch 07/29/20 09:03:06 PM
#23   Hoping for a green week here this week! zmster2033 07/26/20 11:06:59 PM
#22   Waitin... StockRoomBully 07/26/20 06:40:35 PM
#21   Important wait.... StockRoomBully 07/17/20 03:33:44 PM
#20   Any news this fly pass cod* low float StockRoomBully 07/14/20 04:17:38 PM
#19   Good chance to turn, 4$ seems to establish Klinsmann 07/14/20 02:32:42 PM
#18   Welcome folks. What do ya think of this Gem? StockRoomBully 07/14/20 11:53:46 AM
#17   Same here Klinsmann 07/14/20 03:20:41 AM
#16   On the radar screen. nathanial 07/13/20 06:33:29 PM
#15   Qualigen Therapeutics CEO Issues Letter to Stockholders StockRoomBully 07/13/20 09:22:30 AM
#14   Early Bird get the first worm. lol StockRoomBully 07/12/20 07:56:59 PM
#13   Corporate execs to get BONUS StockMonster100 07/12/20 11:51:12 AM
#12   One small step for mankind 2 Giant leap StockRoomBully 07/10/20 04:55:39 PM
#11   Great potential here StockRoomBully 07/09/20 10:41:26 AM
#10   Not enough tests to go around....constant shortage. 0whammies 07/06/20 07:49:24 PM
#9   Hope so, but QLGN is dead money. RTTR Mikems 07/06/20 02:50:47 PM
#8   $QLGN MUST READ - people need to realize StockRoomBully 07/05/20 06:31:37 PM
#7   Waitin' on the crowd. We here. A-Team! StockRoomBully 07/02/20 12:59:44 PM
#6   Trying to decide if I should cover at Disquisition 07/02/20 09:42:57 AM
#5   A-Team! StockRoomBully 07/02/20 09:34:53 AM
#4   Qualigen Therapeutics Receives U.S. Patent Notice of Allowance StockRoomBully 07/02/20 09:01:49 AM
#3   Recent News StockRoomBully 07/02/20 09:00:28 AM
#2   Qualigen’s AS1411 cancer drug candidate uses synthetic DNA, StockRoomBully 07/02/20 08:59:57 AM
#1   https://www.qualigeninc.com/ StockRoomBully 07/02/20 08:59:24 AM
Consent Preferences